drugset / Trial / NCT04166435
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II, non-randomized, open-label study to evaluate temozolomide in combination with olaparib in patients with MGMT promoter hypermethylated advanced colorectal cancer.
Timeline
- Start
- 2020-06-17
- Primary completion
- 2022-01-06
- Completion
- 2023-06-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 150 mg | Oral |
| Subject | Temozolomide | Small molecule | 75 mg/m2 | Oral |